Nicotine pouches remain at the centre of the global harm‑reduction conversation — and a major new peer‑reviewed review helps explain why. A new narrative review by Konstantinos Farsalinos in Internal and Emergency Medicine reinforces a clear message: modern, tobacco‑free nicotine pouches sit at the very lowest end of the toxicant‑exposure continuum. Chemical analyses and biomarker…
Following GINN’s recent market‑insights visit to Lebanon, led by our Director Shem Baldeosingh, we continue to learn from frontline experts who see the realities of nicotine use, smoking, and harm reduction every day. This week, Dr Vera Matta (@dr.veramatta), a respected clinician and public health communicator, highlighted an important point while reviewing REBEL White Slim…
A Deep Dive into the Future of Novel NicotineWe wish to share the latest episode of the Tobacco Asia / InterTabac podcast, where GINN’s Director Shem Baldeosingh joins Thomas Schmid for a wide-ranging conversation on the evolution of safer nicotine products and the global landscape. In this episode, Shem reflects on GINN’s journey since our…
🇨🇳 China Confirms Nicotine Pouches Are Now Under the State Tobacco Monopoly China’s move to classify nicotine pouches within the state tobacco monopoly is now confirmed not only by specialist regulatory trackers but also by 2Firsts, which has published detailed reporting on the shift https://lnkd.in/gnx-jTTd The direction of travel is clear: a domestic market increasingly…
This submission is provided on behalf of the Global Institute for Novel Nicotine (GINN), which advocates for proportionate, science-based regulation that recognises tobacco harm reduction (THR) as a legitimate public health strategy Our focus is on the necessary regulation of nicotine products, specifically nicotine pouches, which are currently available on the UK market but operate…